Acumen Pharmaceuticals, Inc. Finance Lease, Liability, Undiscounted Excess Amount
Acumen Pharmaceuticals, Inc. (ABOS) had Finance Lease, Liability, Undiscounted Excess Amount of $7.00 thousand as of 2023-12-31, per its 10-K filed 2024-03-26.
Discontinued › Notes › Leases
us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount · last filed 2024-03-26
- 2023-12-31: Finance Lease, Liability, Undiscounted Excess Amount $7.00K.
| Period end | Finance Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2023-12-31 | $7.00K 10-K · filed 2024-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |